Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alitretinoin topical - Ligand Pharmaceuticals

Drug Profile

Alitretinoin topical - Ligand Pharmaceuticals

Alternative Names: 9-cis Retinoic acid; 9-CRA; ALRT 1057; LG 1057; LGD 1057; LGN 1057; Panretin

Latest Information Update: 04 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ligand Pharmaceuticals
  • Class Antineoplastics; Keratolytics; Retinoids; Skin disorder therapies; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Kaposi's sarcoma

Most Recent Events

  • 01 Apr 2019 ADVANZ Pharma acquires global marketing rights of alitretinoin from Eisai
  • 13 Mar 2015 Launched for Kaposi's sarcoma in Argentina (Topical) before March 2015
  • 18 Dec 2013 Elan Corporation has been acquired and merged into Perrigo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top